Mitochondrial Targeting Strategies in Cancer Therapeutics

Cancer cells often exhibit altered mitochondrial function to satisfy elevated bioenergetic and biosynthetic demands. A spectrum of therapeutic approaches has emerged to exploit mitochondrial vulnerabilities, including direct inhibition of respiratory chain complexes, targeted delivery of small molecules to the organelle, modulation of mitochondrial‐driven reactive oxygen species and disruption of mitochondrial biogenesis. In parallel, agents originally developed for other indications have been repurposed to interfere selectively with mitochondrial metabolism in cancer cells. These strategies aim to overcome drug resistance, eradicate quiescent or stem‐like tumour cell populations and augment the efficacy of conventional therapies such as chemotherapy and radiotherapy. Advances in organelle‐targeting chemistry, coupled with deeper insight into metabolic plasticity, have delivered compounds that accumulate within mitochondria, perturb mitochondrial membrane potential and trigger cell death in metabolically stressed microenvironments. Collectively, these approaches illustrate the global significance of mitochondrial targeting as a versatile platform for next‐generation cancer therapeutics.

Research from Nature Portfolio

Recent studies have highlighted oxidative phosphorylation as a critical liability in therapy‐resistant breast cancers. In metastatic oestrogen receptor‐positive models, comprehensive metabolomic and genomic analyses revealed a subset of tumours reliant on mitochondrial respiration. Administration of a potent complex I inhibitor dramatically suppressed tumour growth, particularly in cases harbouring specific PIK3CA/AKT1 mutations, and reshaped antioxidant and pentose phosphate pathway metabolites in vivo. This work underscores the predictive value of mitochondrial gene expression for patient prognosis and supports complex I inhibition as a strategy for treatment-resistant disease.

Another line of investigation has refined an antiglycolytic agent by attaching a lipophilic moiety to drive mitochondrial accumulation. The resulting mitochondria-targeted derivative exhibited a 100-fold increase in potency against lung cancer cells and effectively prevented both primary tumour development and brain metastasis in mouse models. Mechanistically, the compound inhibited oxidative phosphorylation, elevated mitochondrial reactive oxygen species, inactivated AKT/mTOR signalling and induced autophagic cell death without observable toxicity, signalling promise for clinical translation.

Mitochondrial Targeting Strategies in Cancer Therapeutics publication trend

The graph below shows the total number of articles in mitochondrial targeting strategies in cancer therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Oxidative phosphorylation (OXPHOS): Mitochondrial process by which electrons are transferred through the respiratory chain to generate ATP from ADP and inorganic phosphate.

Mitochondrial complex I: The first enzyme complex of the respiratory chain, also known as NADH dehydrogenase, which transfers electrons to ubiquinone.

Cancer stem cells (CSCs): A subpopulation of tumour cells with self-renewal capacity and high tumourigenic potential, often implicated in relapse and metastasis.

Exosomes: Nano-sized extracellular vesicles released by cells that transport proteins, lipids and nucleic acids to distant recipient cells.

Triphenylphosphonium (TPP+) cation: A lipophilic, positively charged moiety used to facilitate accumulation of conjugated compounds within mitochondria driven by membrane potential.

References

1. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. Nature Communications (2023).
2. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nature Communications (2019).
3. Exosomal transfer leads to chemoresistance through oxidative phosphorylation-mediated stemness phenotype in colorectal cancer. Theranostics (2023).
4. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. Oncotarget (2015).